Patients reasons for obtaining psychotropic medications without a prescription at retail pharmacies in Central Saudi Arabia

References

1. ↵
   1. Ohayon MM,
   2. Lader MH

   (2002) Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychiatry 63, 817–825.
2. ↵
   1. Wiechers IR,
   2. Leslie DL,
   3. Rosenheck RA

   (2013) Prescribing of psychotropic medications to patients without a psychiatric diagnosis. Psychiatr Serv 64, 1243–1248.
3. ↵
   1. Sawalha AF

   (2008) A descriptive study of self-medication practices among Palestinian medical and nonmedical university students. Res Social Adm Pharm 4, 164–172.
4. ↵
   1. Bin Abdulhak AA,
   2. Altannir MA,
   3. Almansor MA,
   4. Almohaya MS,
   5. Onazi AS,
   6. Marei MA,
   7. et al.

   (2011) Non prescribed sale of antibiotics in Riyadh, Saudi Arabia: a cross sectional study. BMC Public Health 11, 538.
5. ↵
   1. Al-Mohamadi A,
   2. Badr A,
   3. Bin Mahfouz L,
   4. Samargandi D,
   5. Al Ahdal A

   (2013) Dispensing medications without prescription at Saudi community pharmacy: Extent and perception. Saudi Pharm J 21, 13–18.
6. ↵
   1. Al-Sayed AA,
   2. Al-Rashoudi AH,
   3. Al-Eisa AA,
   4. Addar AM,
   5. Al-Hargan AH,
   6. Al-Jerian AA,
   7. et al.

   (2014) Sedative Drug Use among King Saud University Medical Students: A Cross-Sectional Sampling Study. Depress Res Treat 2014, 378738.
7. ↵
   1. Chang CM,
   2. Wu EC,
   3. Chen CY,
   4. Wu KY,
   5. Liang HY,
   6. Chau YL,
   7. et al.

   (2013) Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study. Br J Clin Pharmacol 75, 1125–1133.
8. ↵
   1. Ravera S,
   2. van Rein N,
   3. de Gier JJ,
   4. de Jong-van den Berg LT

   (2011) Road traffic accidents and psychotropic medication use in The Netherlands: a case-control study. Br J Clin Pharmacol 72, 505–513.
9. ↵
   1. Malekshahi T,
   2. Tioleco N,
   3. Ahmed N,
   4. Campbell AN,
   5. Haller D

   (2015) Misuse of atypical antipsychotics in conjunction with alcohol and other drugs of abuse. J Subst Abuse Treat 48, 8–12.
10. ↵
    1. Schifano F

    (2014) Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 28, 491–496.
11. ↵
    1. Williams LJ,
    2. Pasco JA,
    3. Stuart AL,
    4. Jacka FN,
    5. Brennan SL,
    6. Dobbins AG,
    7. et al.

    (2015) Psychiatric disorders, psychotropic medication use and falls among women: an observational study. BMC Psychiatry 15, 75.
12. ↵
    1. Wadsworth EJ,
    2. Moss SC,
    3. Simpson SA,
    4. Smith AP

    (2005) Psychotropic medication use and accidents, injuries and cognitive failures. Hum Psychopharmacol 20, 391–400.
13. ↵
    1. Food and Drug Administration

    (2007) FDA Proposes New Warnings About Suicidal Thinking, Behavior in Young Adults Who Take Antidepressant Medications: Office of the Commissioner, Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108905.htm. cited 2015 Oct 29.
14. ↵
    1. Brooks JO,
    2. Hoblyn JC

    (2007) Neurocognitive costs and benefits of psychotropic medications in older adults. J Geriatr Psychiatry Neurol 20, 199–214.
15. 1. Van Strien AM,
    2. Koek HL,
    3. van Marum RJ,
    4. Emmelot-Vonk MH

    (2013) Psychotropic medications, including short acting benzodiazepines, strongly increase the frequency of falls in elderly. Maturitas 74, 357–362.
16. ↵
    1. Huybrechts KF,
    2. Rothman KJ,
    3. Silliman RA,
    4. Brookhart MA,
    5. Schneeweiss S

    (2011) Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 183, E411–E419.
17. ↵
    1. Abay SM,
    2. Amelo W

    (2010) Assessment of self-medication practices among medical, pharmacy, and health science students in gondar university, ethiopia. J Young Pharm 2, 306–310.
18. ↵
    1. Kroenke K,
    2. Spitzer RL,
    3. Williams JBW

    (2001) The PHQ-9: Validity of a brief depression severity measure. J Gen Intern Med 16, 606–613.
19. ↵
    1. Manea L,
    2. Gilbody S,
    3. McMillan D

    (2012) Optimal cut-off score for diagnosing depression with the Patient Health Questionnaire (PHQ-9): a meta-analysis. CMAJ 184, E191–E196.
20. ↵
    1. Spitzer RL,
    2. Kroenke K,
    3. Williams JB,
    4. Löwe B

    (2006) A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 166, 1092–1097.
21. ↵
    1. Food and Drug Administration

    (2014) Escitalopram Clinical review: FDA, Available from: http://www.fda.gov/downloads/drugs/developmentapprovalprocess/developmentresources/ucm226541.pdf. cited 2015 Oct 29.
22. ↵
    1. Jiang HY,
    2. Chen HZ,
    3. Hu XJ,
    4. Yu ZH,
    5. Yang W,
    6. Deng M,
    7. et al.

    (2015) Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 13, 42–50.
23. ↵
    1. Mortensen JK,
    2. Larsson H,
    3. Johnsen SP,
    4. Andersen G

    (2014) Impact of prestroke selective serotonin reuptake inhibitor treatment on stroke severity and mortality. Stroke 45, 2121–2123.
24. ↵
    1. Buckley NA,
    2. Dawson AH,
    3. Isbister GK

    (2014) Serotonin syndrome. BMJ 348, g1626.
25. ↵
    1. Rummel-Kluge C,
    2. Komossa K,
    3. Schwarz S,
    4. Hunger H,
    5. Schmid F,
    6. Lobos CA,
    7. et al.

    (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res 123, 225–233.
26. ↵
    1. De Hert M,
    2. Detraux J,
    3. van Winkel R,
    4. Yu W,
    5. Correll CU

    (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8, 114–126.
27. ↵
    1. Bostwick JR,
    2. Guthrie SK,
    3. Ellingrod VL

    (2009) Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 29, 64–73.
28. ↵
    1. Belvederi Murri M,
    2. Guaglianone A,
    3. Bugliani M,
    4. Calcagno P,
    5. Respino M,
    6. Serafini G,
    7. et al.

    (2015) Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 15, 45–62.
29. ↵
    1. Wu CS,
    2. Tsai YT,
    3. Tsai HJ

    (2015) Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. J Am Heart Assoc, 4.
30. ↵
    1. Ray WA,
    2. Chung CP,
    3. Murray KT,
    4. Hall K,
    5. Stein CM

    (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360, 225–235.
31. ↵
    1. Drew L

    (2013) Clozapine and agranulocytosis: re-assessing the risks. Australas Psychiatry 21, 335–337.
32. ↵
    1. Wong J,
    2. Delva N

    (2007) Clozapine-induced seizures: recognition and treatment. Can J Psychiatry 52, 457–463.
33. ↵
    1. Ronaldson KJ,
    2. Fitzgerald PB,
    3. McNeil JJ

    (2015) Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 132, 231–240.
34. ↵
    1. Schifano F

    (2014) Misuse and abuse of pregabalin and gabapentin: cause for concern? CNS Drugs 28, 491–496.
35. ↵
    1. Olfson M,
    2. King M,
    3. Schoenbaum M

    (2015) Benzodiazepine use in the United States. JAMA Psychiatry 72, 136–142.
36. ↵
    1. Murphy Y,
    2. Wilson E,
    3. Goldner EM,
    4. Fischer B

    (2016) Benzodiazepine Use, Misuse, and Harm at the Population Level in Canada: A Comprehensive Narrative Review of Data and Developments Since 1995. Clin Drug Investig 36, 519–530.
37. ↵
    1. Ministry of Health. Formularly drug list

    (2012) (MOH, Saudi Arabia) Available from: http://www.moh.gov.sa/Portal/WhatsNew/Documents/MOHF_DRUG_LIST_CD.pdf. cited 2016 May 7.
38. ↵
    1. Yousef AMM,
    2. Al-Bakri AG,
    3. Bustanji Y,
    4. Wazaify M

    (2008) Self-medication patterns in Amman, Jordan. Pharm World Sci 30, 24–30.
39. ↵
    1. Balamurugan E,
    2. Ganesh K

    (2011) Prevalence and pattern of self medication use in coastal regions of south india. Br J Med Pract. 2011; Balamurugan E, Ganesh K. Prevalence and pattern of self medication use in coastal regions of south india. Br J Med Pract 4, a428.
40. ↵
    1. Jalilian F,
    2. Hazavehei SM,
    3. Vahidinia AA,
    4. Jalilian M,
    5. Moghimbeigi A

    (2013) Prevalence and related factors for choosing self-medication among pharmacies visitors based on health belief model in Hamadan Province, west of Iran. J Res Health Sci 13, 81–85.
41. ↵
    1. Al-Qadhi W,
    2. Ur Rahman S,
    3. Ferwana MS,
    4. Abdulmajeed IA

    (2014) Adult depression screening in Saudi primary care: prevalence, instrument and cost. BMC Psychiatry 14, 190.
42. ↵
    1. Al-Shehri SZ,
    2. Sabra AA,
    3. Taha AZ,
    4. Khamis AH,
    5. Hafez AS

    (2012) Depression and Anxiety among Males Attending Primary Health Care Centers, Eastern Saudi Arabia: Prevalence and Predictors. Life Science Journal 9, 1–5.
43. ↵
    1. Council of Cooperative Health Insurance

    (2015) Rules and Regulations (Council of Cooperative Health Insurance, Saudi Arabia) [cited 2015 Oct 30], Available from: http://www.cchi.gov.sa/en/Rules/Pages/document.aspx.
44. ↵
    1. Alosaimi FD,
    2. Alshehri Y,
    3. Alfraih I,
    4. Alghamdi A,
    5. Aldahash S,
    6. Alkhuzayem H,
    7. et al.

    (2015) Psychosocial correlates of using faith healing services in Riyadh, Saudi Arabia: a comparative cross-sectional study. Int J Ment Health Syst 9, 8.
45. ↵
    1. Trenque T,
    2. Piednoir D,
    3. Frances C,
    4. Millart H,
    5. Germain ML

    (2002) Reports of withdrawal syndrome with the use of SSRIs: a case/non-case study in the French Pharmacovigilance database. Pharmacoepidemiol Drug Saf 11, 281–283.